Cullinan Therapeutics Stock (NASDAQ: CGEM)

Cullinan Therapeutics (NASDAQ:CGEM) Stock, Quote.Headers.trade-ideas

Cullinan Therapeutics

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Headquarters_Rahway-Site-Entrance_HI

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

Trading Ideas

General

CGEM

Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck&#39;s pipeline for treating B-cell malignancies and autoimmune diseases. The deal, valued at up to $1.3 billion, is expected to close in Q3 2024.

Merck&#39;s $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan&#39;s Investigational Drug, Says Analyst

Intraday Update

Markets

Movers

ADXN

ALTM

ANVS

APLD

ATXI

CALT

CAUD

CJJD

CLVR

CSSE

CVEO

CYCC

DAVE

DCPH

ENLV

FLGC

FTEL

FULT

HOPE

HTLF

IBRX

INHD

IONM

ISUN

KYTX

MESO

MPLN

MULN

NUZE

NWGL

OCGN

PAHC

PRME

SLNO

SOFI

SSKN

TCJH

TSLA

ZVSA

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Tesla logo

EXAI

PACB

PARA

ROKU

TELL

TNDM

Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics Inc

Capgemini SE

In the preceding three months, 7 analysts have released ratings for ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $227.57, accompanied by a high estimate of $280.00 and a low estimate of $180.00. Witnessing a positive shift, the current average has risen by 3.68% from the previous average price target of $219.50.
<img src="https://www.benzinga.com/files/images/story/2024/1727182881_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of ResMed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$280.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Underperform</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$236.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$206.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$251.00</td>
<td>$238.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$236.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$204.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ResMed compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of ResMed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ResMed's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RMD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ResMed analyst ratings.</a>
<h2>Discovering ResMed: A Closer Look</h2>
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
<h3>ResMed: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: ResMed displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 9.01%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: ResMed's net margin excels beyond industry benchmarks, reaching 23.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ResMed's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.16% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): ResMed's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.27% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: ResMed's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: ResMed Through The Eyes Of 7 Analysts

In the latest quarter, 14 analysts provided ratings for Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $177.5, a high estimate of $190.00, and a low estimate of $161.00. This upward trend is apparent, with the current average reflecting a 3.04% increase from the previous average price target of $172.27.
<img src="https://www.benzinga.com/files/images/story/2024/1727182872_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Procter &amp; Gamble by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$174.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$186.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Michael Pohn</td>
<td>DZ Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$179.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$164.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Kaumil Gajrawala</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$175.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$189.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$161.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$174.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Robert Ottenstein</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$176.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$177.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Procter &amp; Gamble. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Procter &amp; Gamble compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Procter &amp; Gamble's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Procter &amp; Gamble analyst ratings.</a>
<h2>Delving into Procter &amp; Gamble's Background</h2>
Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.
<h3>Unraveling the Financial Story of Procter &amp; Gamble</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Procter &amp; Gamble's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -0.1%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Procter &amp; Gamble's net margin is impressive, surpassing industry averages. With a net margin of 14.91%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Procter &amp; Gamble's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 6.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.53%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.67.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Procter & Gamble: Insights From 14 Analyst Reviews

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.5, along with a high estimate of $19.00 and a low estimate of $18.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1727182845_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of NeoGenomics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NeoGenomics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NeoGenomics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of NeoGenomics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of NeoGenomics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NEO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NeoGenomics analyst ratings.</a>
<h2>Discovering NeoGenomics: A Closer Look</h2>
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
<h3>NeoGenomics: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: NeoGenomics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 11.97%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NeoGenomics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -11.33%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.03%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.14%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.66.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For NeoGenomics

Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $70.69, with a high estimate of $90.00 and a low estimate of $54.00. Highlighting a 14.63% decrease, the current average has fallen from the previous average price target of $82.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1727182837_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Procore Technologies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$73.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Trout</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$70.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$82.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Tom Roderick</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$63.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$73.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$54.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Robert Trout</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Tom Roderick</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$86.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Procore Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Procore Technologies compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Procore Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Procore Technologies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PCOR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Procore Technologies analyst ratings.</a>
<h2>Unveiling the Story Behind Procore Technologies</h2>
Procore Technologies Inc is a cloud-based construction management software company. It generates revenue through subscriptions for access to its software products. The company's products include Design Coordination, BIM, Field Productivity, Project Financials, Invoice Management, Portfolio Financials, Capital Planning, Accounting Integrations, and Analytics. The software products are hosted on its cloud-based SaaS construction management platform. Subscriptions are sold for a fixed fee and revenue is recognized ratably over the term of the subscription.
<h3>A Deep Dive into Procore Technologies's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Procore Technologies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 24.42% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Procore Technologies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -2.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Procore Technologies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.52%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Procore Technologies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.33%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PCOR

Critical Insights From Procore Technologies Analyst Ratings: What You Need To Know

Upgrades to Nuvei's suite of seamless Embedded Payments solutions unlocks new growth opportunities for businesses of all sizes

NVEI

Nuvei For Platforms Launches New Features

WIIM

RDZN

Roadzen shares are trading higher after the company announced a one-year extension for its insider lock-up period.

Macro Economic Events

Econ #s

Economics

House Price Index (MoM) (Jul) + 0.1% vs +0.2% Est.,

8 analysts have shared their evaluations of Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.0, with a high estimate of $82.00 and a low estimate of $53.00. Observing a 1.04% increase, the current average has risen from the previous average price target of $68.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1727182824_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Dayforce by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bhavin Shah</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jared Levine</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dayforce. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dayforce compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Dayforce's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Dayforce's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dayforce analyst ratings.</a>
<h2>About Dayforce</h2>
Dayforce provides payroll and human capital management solutions targeting clients with 100-100,000 employees. Following the 2012 acquisition of Dayforce, Dayforce pivoted away from its legacy on-premises Bureau business to become a cloud HCM provider. As of fiscal 2022, about 80% of group revenue was derived from the flagship Dayforce platform geared toward enterprise clients. The remaining revenue is about evenly split between cloud platform Powerpay, targeting small businesses in Canada, and legacy Bureau products.
<h3>Breaking Down Dayforce's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Dayforce displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 15.69%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Dayforce's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -0.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dayforce's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.07%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Dayforce's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Dayforce's debt-to-equity ratio is below the industry average. With a ratio of 0.5, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Dayforce

4 analysts have expressed a variety of opinions on Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.88, a high estimate of $8.00, and a low estimate of $4.50. This upward trend is apparent, with the current average reflecting a 23.79% increase from the previous average price target of $4.75.
<img src="https://www.benzinga.com/files/images/story/2024/1727182810_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Compass by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Compass. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Compass compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Compass's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Compass's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COMP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Compass analyst ratings.</a>
<h2>Delving into Compass's Background</h2>
Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.
<h3>Unraveling the Financial Story of Compass</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Compass displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 13.83%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Compass's net margin excels beyond industry benchmarks, reaching 1.22%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Compass's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.68% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Compass's ROA excels beyond industry benchmarks, reaching 1.75%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.32, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COMP

Key Takeaways From Compass Analyst Ratings

Hispanics, who account for 22% of Florida's electorate with 2.75 million voters, are showing increasing support for cannabis legalization. In a recent poll conducted by TelevisaUnivision and Media Predict, 60% of Hispanic voters in the state expressed either a definite or probable &#8220;yes&#8221; on Amendment 3, which seeks to legalize recreational cannabis for adults aged 21 and older.&nbsp;
This is a 2% rise from last month's numbers, highlighting growing acceptance within this key demographic. For cannabis investors, this trend signals potential market expansion in Florida, making the Hispanic electorate an essential group to watch as it could shape the future of the state's cannabis industry.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">High Support Among Non-Hispanic Voters</h3>
Among non-Hispanic voters, 63% showed similar enthusiasm for cannabis legalization. The <a href="https://uci.sharepoint.com/:p:/s/KWTeam/Eeh7819q-VhCkaX-fpsvOVsBQMO7sxoSN1b2BpFw3fbzdA?rtime=JcOK8MDY3Eg">poll</a>, conducted online from September 12-16 with 1,155 likely voters, highlights the growing acceptance of recreational cannabis across diverse voter groups. Investors should take note: if approved in the November election, <a href="https://www.benzinga.com/topic/florida-cannabis">Florida&#8217;s cannabis market</a> could undergo a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38037571/floridas-6b-cannabis-market-anticipates-400-growth-following-court-decision-allowin">400% growth</a>, providing new opportunities for business development.
<h3 class="wp-block-heading">Economic Concerns Remain Paramount</h3>
In addition to cannabis, Florida Politics <a href="https://floridapolitics.com/archives/697038-poll-hispanic-voters-are-warming-to-florida-ballot-measures-on-recreational-pot-abortion/">reported</a> that abortion rights have also captured the attention of Hispanic voters. Amendment 4, which seeks to protect abortion access until fetal viability (around 24 weeks), had consistent support from 63% of Hispanic voters. The intensity of this support grew, with 41% now expressing certainty in their vote, up from 39% last month.
While cannabis and abortion are hot topics, economic issues remain at the top of the list for Hispanic voters. A staggering 80% of respondents identified the rising cost of living as the most pressing issue, followed by inflation at 79%.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40879364/young-republicans-break-ranks-to-back-cannabis-legalization-is-the-gop-ready-for-a-shift-in-the-">Young Republicans Break Ranks To Back Cannabis Legalization—Is The GOP Ready For A Shift In The Status Quo?</a>
<h3 class="wp-block-heading">Will It Be Enough?</h3>
As Florida and the natioin approach the upcoming <a href="https://www.benzinga.com/topic/2024-election">November 2024 elections,</a> the outcome remains uncertain. National dynamics, such as concerns over the economy and immigration, may overshadow cannabis reform as a top priority for voters. 
While V.P. Kamala Harris and her running mate <a href="https://www.benzinga.com/general/politics/24/09/40844701/trump-harris-might-not-debate-again-but-their-running-mates-will-what-voters-should-know-about-w">Tim Walz </a>support <a href="https://www.benzinga.com/markets/cannabis/24/09/40846480/cannabis-experts-say-weed-reform-is-a-race-against-time-is-the-dea-delaying-bidens-rescheduling-">federal cannabis reform</a>, Donald Trump&#8216;s recent <a href="https://www.benzinga.com/markets/cannabis/24/08/40666944/donald-trump-supports-cannabis-legalization-in-florida-game-changer-and-huge-blow-to-ron-desanti">backing </a>for legalization in Florida presents a different challenge. His stance is more of a concept rather than a detailed policy.
Trump's endorsement could energize conservative voters who may previously have been ambivalent on the issue, potentially undercutting Harris's advantage in traditionally progressive areas.&nbsp;
Despite strong support for Amendment 3 among Hispanic voters, the broader electorate's focus on economic and social issues in such a divided political landscape may limit its impact on swaying the cannabis legalization effort.
Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>), Curaleaf Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), and Ayr Wellness Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>) are some of the<a href="https://www.benzinga.com/cannabis"> key players</a> in Florida's medical cannabis market. Trulieve, in particular, dominates the Florida market with a large number of dispensaries. If Amendment 3 passes, these companies could see significant stock movement as they transition to serving a broader, recreational consumer base.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40926862/desantis-targets-one-big-weed-company-funding-floridas-legalization-campaign-cites-corporate-int">DeSantis Targets &#8216;One Big Weed Company&#8217; Funding Florida&#8217;s Legalization Campaign, Citing &#8216;Corporate Interests&#8217;</a>

Cannabis

Government

Market Summary

Regulations

Politics

AYRWF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

TCNNF

Your Cousins In Florida Like Their Weed: Why Hispanic Voters Could Tip The Scale For Cannabis,Will It Be Enough?

Maxim Group analyst Michael Okunewitch initiates coverage on FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) with a Buy rating and announces Price Target of $12.

Price Target

Initiation

FBLG

Maxim Group Initiates Coverage On FibroBiologics with Buy Rating, Announces Price Target of $12

SPOT

Spotify Says AI Playlist In English Rolling Out In Beta To Premium Users On Android & iOS Devices In The U.S., Canada, Ireland, & New Zealand

RBC Capital analyst Ken Herbert reiterates AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) with a Outperform and maintains $85 price target.

Reiteration

RBC Capital Reiterates Outperform on AAR, Maintains $85 Price Target

The succession process, announced in April 2024, has been completed; Alejandro Stengel will be stepping down from his position.
Grupo Supervielle S.A. (NYSE:<a href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) (BYMA: SUPV) ("Supervielle" or the "Company"), a universal financial services group headquartered in Argentina with a nationwide presence, announced today that Mr. Gustavo Manriquez has been appointed as CEO of Banco Supervielle, effective October 1, 2024.
Prior to his appointment as CEO of Banco Supervielle, and since 2016, Gustavo served as CEO and General Manager of Banco Macro. During his tenure, he focused on positioning the bank as one of the leading private franchises in the country and developed a digital strategy that facilitated a comprehensive transformation of the value proposition across all customer segments. He brings over 30 years of experience in the Argentine financial industry, where he has held several executive positions and consistently driven growth through strategic partnerships and the implementation of innovative digital solutions throughout his career. Previously, he led the Retail and SMEs divisions at Scotiabank Uruguay. Prior to that, Gustavo had an extensive career at Citibank, both in Argentina and abroad. He holds a bachelor's degree in business administration from Universidad de Belgrano and a postgraduate degree in Finance from CEMA, Centro de Estudios Macroeconómicos. Additionally, he completed the Executive Development Program at the Instituto de Altos Estudios Empresariales (IAE) and also holds an MBA from IAE.

Management

SUPV

Grupo Supervielle S.A. Announces The Appointment Of Gustavo Manriquez As CEO Of Banco Supervielle

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) spot ETFs recorded a small net inflow of $4.56 million on Monday as miner revenues signal a potential uptrend <a href="https://www.benzinga.com/money/bitcoin-price-prediction">in the making.</a>
What Happened: Significant contributions came from Fidelity&#8217;s ETF (CBOE: FBTC), which added $24.93 million, and the BlackRock ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), with an inflow of $11.54 million.
However, Grayscale's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#OTC">GBTC</a>) recorded a notable outflow of $40.33 million, reflecting mixed sentiment within the market, according to <a href="https://sosovalue.xyz/assets/etf/us-btc-spot">data</a> from SoSo Value.
Meanwhile, Ethereum spot ETFs experienced a major outflow of $79.21 million, largely driven by a $80.55 million outflow from Grayscale's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETHE#NYSE">ETHE</a>), though Bitwise's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETHW#NYSE">ETHW</a>) saw a modest inflow of $1.34 million, <a href="https://sosovalue.xyz/assets/etf/us-eth-spot">data</a> shows.
Bitcoin continues to hover near $63,500, up just 0.1% over the past 24 hours, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) has seen a slight decline, trading down 0.1% at $2,642.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40989892/bitcoins-22-rally-isnt-enough-it-must-break-august-high-to-overcome-downtrend-bitfinex-ana">Bitcoin&#8217;s 22% Rally Isn&#8217;t Enough, It Must Break August High To Overcome Downtrend, Bitfinex Analysts Say</a>
Why It Matters: As institutional interest in Bitcoin ETFs persists, industry experts are weighing in on what could drive prices in the near term.
Eric Balchunas, Senior ETF Analyst at Bloomberg, <a href="https://x.com/EricBalchunas/status/1838296036772593716">highlighted</a> BlackRock&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) method of securing its Bitcoin holdings, stating, &#8220;BlackRock runs their own blockchain node and ensures that Coinbase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) deposits Bitcoin directly on-chain within 12 hours of instruction. This is why they, and other major ETF issuers, are trusted by America&#8217;s advisors—they've perfected this process over decades.&#8221;
Balchunas&#8217; comments underline the trust institutions place in BlackRock's processes, which remain key to the continued confidence in Bitcoin ETFs.
On the broader market dynamics, Iliya Kalchev, a Nexo Dispatch Analyst, pointed out the potential impact of Bitcoin miners on price action. 
"Bitcoin miner revenues remain at multi-year lows, creating the potential for price appreciation if miners start distributing Bitcoin at higher prices to sustain their operations," he told Benzinga. 
Kalchev added that traders, rather than investors, could be the primary drivers of Bitcoin's short-term moves, with Bitcoin open interest at over $25 billion. 
He highlighted that a breakout above $66,000 would signal growing optimism as the options market currently favors calls above that level.
Ilia Otychenko, Lead Analyst at CEX.IO, provided a technical analysis of Bitcoin's current resistance levels. 
"Bitcoin remains near the 200-day SMA and the previous local high, both key resistance levels. A sustained break above the 200-day SMA could drive Bitcoin toward the $66,000–$67,300 supply zone. However, failure at these levels may lead to consolidation or a drop to $62,700," Otychenko explained. 
He also noted that, while Bitcoin has tested major resistance, low trading volumes during the attempt have prevented further gains.
Despite short-term uncertainties, Otychenko remains bullish on Bitcoin's longer-term outlook. 
"The weekly RSI has broken above its descending resistance trendline, a historically bullish indicator. If this pattern holds, Bitcoin could be on track for a new all-time high in the coming months," he added.
What&#8217;s Next: Industry experts will have the opportunity to explore these themes in depth at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40990471/donald-trumps-crypto-portfolio-surges-by-over-800k-in-september">Donald Trump&#8217;s Crypto Portfolio Surges By Over $800K In September</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

COIN

ETHE

ETHW

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

GBTC

IBIT

Bitcoin ETFs See $4.5M Inflow, But Miners Could Actually Cause The Next Big Move Up

Benzinga will host its latest virtual event, Managing Volatile Markets with 0DTE Options, on Thursday, Sept. 26, at 11 a.m. ET. This event will feature Robert A. Hocking, senior vice president and global head of product innovation at Cboe Global Markets, who will discuss the growing role of zero-days-to-expiration (0DTE) options in navigating<a href="https://www.benzinga.com/markets"> unpredictable market conditions</a>.
<h3 class="wp-block-heading">Exploring 0DTE Options For Volatile Markets</h3>
As market volatility remains a central concern for traders, using short-dated options like 0DTE has gained momentum. These options, which expire the same day they are traded, allow for quick adjustments and may offer a flexible approach to sudden market movements. 
Hocking is expected to focus on how these options can effectively manage the ups and downs that define today's trading environment.
The webinar will also cover other tools that traders can use, such as VIX products, which track market volatility, and strategies for refining short-term trading decisions during periods of uncertainty. The event aims to provide practical insights into handling fluctuating markets and improving overall trading approaches.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Managing Volatile Markets with 0DTE Options!" width="500" height="281" src="https://www.youtube.com/embed/6B-K5TZbDGU?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
<h3 class="wp-block-heading">Hocking's Perspective</h3>
Hocking brings extensive experience to the discussion. As a senior executive at Cboe Global Markets, he has been involved in product development and innovation in the financial markets. 
Hocking&#8217;s role at Cboe includes overseeing the creation of solutions aimed at helping traders respond to market challenges. This event will give attendees a chance to hear directly from an expert with a deep understanding of the tools and techniques that have become critical in today's market environment.
<h3 class="wp-block-heading">Why Attend?</h3>
With markets continuing to fluctuate, short-term trading strategies have become increasingly relevant. 0DTE options have gained attention for their potential to address volatility head-on, making them an important topic for experienced and newer traders. 
This event will offer guidance on how these options can fit into a broader trading strategy while clarifying market behavior during turbulent times.
<h3 class="wp-block-heading">How To Tune In</h3>
The virtual event will be held on Thursday, Sept. 26, at 11 a.m. ET. Traders of all levels are invited to register through Benzinga's website. The session will offer valuable insights on managing market volatility using short-dated options and other vital tools. As part of Benzinga's ongoing series of virtual events, this webinar presents an opportunity for traders to enhance their understanding of volatility management in a fast-paced market setting. <a href="https://www.benzinga.com/events/managing-volatile-markets-with-0dte-options/">Click here to sign up.</a>
Image: Shutterstock

Events

Master Market Fluctuations With 0DTE Options: Here's What You Need To Know

The Charles Schwab Corporation announced today that it has scheduled a Fall Business Update for institutional investors on Tuesday, October 15th. This Update, which will be held via live public webcast, is part of an ongoing series designed to help the investment community keep abreast of recent developments and management's strategic focus. The program is scheduled to run from 7:30 a.m. - 8:30 a.m. CT, 8:30 a.m. - 9:30 a.m. ET. Participants will include Co-Chairman and Chief Executive Officer Walt Bettinger, President Rick Wurster, Chief Financial Officer Mike Verdeschi, and Managing Director Peter Crawford.
The Update will be accessible at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fschwabevents.com%2Fcorporation&amp;esheet=54125309&amp;newsitemid=20240924368716&amp;lan=en-US&amp;anchor=https%3A%2F%2Fschwabevents.com%2Fcorporation&amp;index=1&amp;md5=8195874710f7f59c05c88cd68e9246dd">https://schwabevents.com/corporation</a>.

SCHW

Schwab Announces Its Fall Business Update On October 15, 2024 Designed To Help The Investment Community Keep Abreast Of Recent Developments And Management's Strategic Focus

SMAR

Smartsheet Shares Halted Pending News

Redbook: US Retail Sales +4.4% Week End Sep 21 vs Year Ago

<a href="https://x.com/davidfaber/status/1838561778239733920" title="https://x.com/davidfaber/status/1838561778239733920">https://x.com/davidfaber/status/1838561778239733920</a>

CNBC's David Faber On X Posts "Smartsheet deal is done. $56.50 a share in cash. Blackstone and Vista Equity the buyers as has been reported. Announcement imminent."

Analyst Soumit Roy from JonesTrading maintained a Buy rating on Cullinan Management (CGEM – Research Report) and keeping the price target at $29.00...

Buy Rating on Cullinan Management: Zipalertinib Shows Promising Efficacy and Market Potential in NSCLC Treatment

BTIG analyst Julian Harrison maintained a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target of $30.00. Ju...

Buy Rating on Cullinan Management Backed by CLN-978's Potential in Autoimmune Therapy

Buy Rating Affirmed for Cullinan Management on Zipalertinib's Market Potential and Efficient Clinical Advancement

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Cullinan Management (CGEM – Research Report), with a price...

Buy Rating Justified: Promising Phase 2b Results and Market Potential for Cullinan Management's Zipalertinib

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Cullinan Management (CGEM – Research Report). The company's shares ...

TD Cowen Keeps Their Buy Rating on Cullinan Management (CGEM)

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of $40....

Stifel Nicolaus Sticks to Their Buy Rating for Cullinan Management (CGEM)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 9/17/2024, According to Top Analysts

An announcement from Cullinan Management ( ($CGEM) ) is now available. Cullinan Therapeutics has announced the initiation of a global Phase 1 clini...

Cullinan Management Advances SLE Treatment with CLN-978 Trial

Buy Rating Affirmed for Cullinan Management Amid Promising Clinical Trials and Market Potential

Wedbush analyst Robert Driscoll initiated coverage with a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target o...

Cullinan Management (CGEM) Gets a Buy from Wedbush

BMRN

FROG

Press Releases

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Earnings

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Cullinan Therapeutics

Cullinan Therapeutics (CGEM) Forecast

Cullinan Therapeutics (NASDAQ:CGEM) Stock, Quote.Headers.trade-ideas